


## Supplemental Information



### SUPPLEMENTAL FIGURE 2

Volume of hospitalization for MIS-C, KD, and both diagnosis. Data shown every 2 weeks from January 2019 to May 2022.

### SUPPLEMENTAL TABLE 5 Algorithm for the Identification of MIS-C Hospitalizations for 2020

#### Algorithm

COVID diagnosis (U07.1) AND Other specified systemic involvement of connective tissue (M35.8) OR

[COVID diagnosis (U07.1) OR Other specified systemic involvement of connective tissue (35.8)] PLUS treatment of MIS-C, as defined by administration of either [IVIG + (either aspirin or an anticoagulant)] OR [(any of: anakinra, infliximab, tocilizumab) + (either aspirin or an anticoagulant)]

IVIG, intravenous immunoglobulin.

<b>SUPPLEMENTAL TABLE 6</b> Patient Demographics and Clinical Characteristics of Patients With a Diagnosis of Both MIS-C and KD				
	<b>MIS-C &amp; KD</b>	<b>MIS-C</b>	<b>KD</b>	<b>P</b>
# Encounters	914	4868	2387	
Age				<.001
<1 y	66 (7.2)	107 (2.2)	479 (20.1)	
1–4 y	374 (40.9)	911 (18.7)	1376 (57.6)	
5–11 y	406 (44.4)	2336 (48)	479 (20.1)	
12–15 y	54 (5.9)	1033 (21.2)	39 (1.6)	
16–20 y	14 (1.5)	481 (9.9)	14 (0.6)	
Sex				.054
Female	331 (36.2)	1921 (39.5)	974 (40.8)	
Race/ethnicity				<.001
Non-Hispanic White	283 (31)	1824 (37.5)	925 (38.8)	
Non-Hispanic Black	260 (28.4)	1372 (28.2)	493 (20.7)	
Hispanic	280 (30.6)	1226 (25.2)	588 (24.6)	
Asian	30 (3.3)	129 (2.6)	212 (8.9)	
Other	61 (6.7)	317 (6.5)	169 (7.1)	
Payor				<.001
Government	525 (57.4)	2577 (52.9)	1176 (49.3)	
Private	341 (37.3)	1973 (40.5)	1064 (44.6)	
Other	48 (5.3)	318 (6.5)	147 (6.2)	
COI				.008
Very low	112 (26.6)	451 (22.1)	231 (23)	
Low	115 (27.3)	480 (23.5)	233 (23.2)	
Moderate	96 (22.8)	423 (20.7)	194 (19.3)	
High	64 (15.2)	457 (22.4)	222 (22.1)	
Very high	34 (8.1)	231 (11.3)	123 (12.3)	
No. of CCC				<.001
0	420 (46)	2386 (49)	1656 (69.4)	
1–2	478 (52.3)	2255 (46.3)	703 (29.5)	
≥3	16 (1.8)	227 (4.7)	28 (1.2)	
Complex chronic condition category				
Neurologic	4 (0.4)	145 (3)	22 (0.9)	<.001
Cardiovascular	218 (23.9)	1274 (26.2)	166 (7)	<.001
Respiratory	0 (0)	46 (0.9)	6 (0.3)	<.001
Renal/urologic	12 (1.3)	120 (2.5)	19 (0.8)	<.001
Gastrointestinal	13 (1.4)	252 (5.2)	30 (1.3)	<.001
Hematologic/immunologic	70 (7.7)	384 (7.9)	110 (4.6)	<.001
Metabolic	315 (34.5)	1340 (27.5)	467 (19.6)	<.001
Congenital/genetic	2 (0.2)	80 (1.6)	18 (0.8)	<.001
Neonatal	2 (0.2)	11 (0.2)	5 (0.2)	.990
Technology	13 (1.4)	183 (3.8)	28 (1.2)	<.001
H-RISK	4.3 (4.1)	5.5 (6.4)	2.1 (2.6)	<.001
Echocardiogram	904 (98.9)	4620 (94.9)	2317 (97.1)	<.001
Shock	200 (21.9)	1883 (38.7)	122 (5.1)	<.001
ECMO	4 (0.4)	69 (1.4)	2 (0.1)	<.001
Epinephrine	166 (18.2)	1526 (31.3)	72 (3)	<.001
Norepinephrine	86 (9.4)	802 (16.5)	30 (1.3)	<.001
Phenylephrine	9 (1)	91 (1.9)	27 (1.1)	.019
Dopamine	2 (0.2)	85 (1.7)	18 (0.8)	<.001
Dobutamine	2 (0.2)	21 (0.4)	0 (0)	.005
Vasopressin	17 (1.9)	134 (2.8)	6 (0.3)	<.001
Milrinone	50 (5.5)	586 (12)	12 (0.5)	<.001
Death	0 (0)	43 (0.9)	0 (0)	<.001

Data are presented as *n* (%) with the exception of H-RISK, which is presented as mean (standard deviation).